Ref ID: 18750
Author:
M. Mares, PhD (Doctor of Philosophy) – Associate Professor1, V. Nastasa, PhD (Doctor of Philosophy) – Associate Professor 1, R. Moraru, PhD (Doctor of Philosophy) – Research Assistant 1, B. Minea, MS – Research Assistant 2, L. Miron, PhD (Doctor of P
Author address:
1Ion Ionescu de la Brad Univ., IASI, Romania, 2Petru Poni Inst. of Macromolecular Chemistry, IASI, Romania.
Full conference title:
52nd Annual ICAAC
Date: 9 September 2014
Abstract:
Background: Over the last two decades, the interest in developing new antifungal drugs and improving the bioavailability of the existing agents is continuously increasing. The new compound MXP-4509 is a nanoparticle-formulated propiconazole derivative, with beta-cyclodextrin being the carrier molecule (figure 1). Methods: We evaluated the antifungal potential of MXP-4509 against 256 Candida isolates belonging to 16 distinct species from four Romanian tertiary hospitals and we compared its activity with those exhibited by two usual azoles. In vitro susceptibility was assessed by following the guidelines of AFST-EUCAST E. Def. 7.1. MICs (minimal inhibitory concentrations) were determined spectrophotometrically after 24 hours of incubation at 36°C. The MIC endpoint was defined as 50% or more reduction in growth compared to that in the active substance-free well. Results: The distribution of MICs for MXP-4509 was very similar with that of voriconazole (MIC50: 0.0312 mg/L versus 0.0156 mg/L; MIC90: 0.25 mg/L versus 0.25 mg/L) while in comparison with fluconazole, it was significantly different (MIC50: 0.0312 mg/L versus 0.5 mg/L; MIC90: 0.25 mg/L versus 16 mg/L). Conclusions: The new triazole MXP-4509 proved to have a good in vitro antifungal activity raising the interest for further pharmacological and microbiological investigations in order to assess its advantages for therapy.
Abstract Number: F-811
Conference Year: 2012
Link to conference website: NULL
New link: NULL
Conference abstracts, posters & presentations
-
Title
Author
Year
Number
Poster
-
v
Teclegiorgis Gebremariam [MS]1, Yiyou Gu [PhD]1, Sondus Alkhazraji [PhD]1, Jousha Quran1, Laura K. Najvar [BS]2, Nathan P. Wiederhold [PharmD]2, Thomas F. Patterson [MD]2, Scott G. Filler [MD]1,3, David A. Angulo (MD)4, Ashraf S. Ibrahim [PhD]1,3*,
2024
91
n/a
-
v
Ruta Petraitiene (US)
2024
90
n/a
-
v
Fabio Palmieri (CH), Junier Pilar
2024
89
n/a
-
v
Evelyne Côté (CA)
2024
88
n/a
-
v
Eliane Vanhoffelen (BE)
2024
87
n/a
-
v
Teclegiorgis Gebremariam, Yiyou Gu, Eman Youssef, Sondus Alkhazraji, Joshua Quran, Nathan P. Wiederhold, Ashraf S. Ibrahim
2024
86
n/a
-
v
Thomas Orasch (DE)
2024
85
n/a
-
v
Julien Alex, Katherine González, Gauri Gangapurwala, Antje Vollrath, Zoltán Cseresnyés, Christine Weber, Justyna A. Czaplewska, Stephanie Hoeppener, Carl-Magnus Svensson, Thomas Orasch, Thorsten Heinekamp, Carlos Guerrero-Sánchez, Marc Thilo Figge, Ulrich S. Schubert, Axel A. Brakhage
2024
84
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
83
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
82
n/a